“Back of the envelope, Phase I and Phase II clinical trials are going to cost $20 to $30 million” per drug, estimates Samuel Scarpino, director of AI + life sciences at Northeastern University and a professor in the practice of health and computer sciences (who is not involved with Intercept).
